奈达铂对食道癌放疗增敏的临床研究

目的：评价同步放化疗对食道癌的疗效。方法：经病理学或细胞学确诊晚期食管癌56例按照随机分组的原则分为奈达铂（NDP-奥先达）＋放疗组（治疗组28例）和单纯放疗组（对照组28例）。两组病例均采用目前标准放疗方案：放射源为医用直线加速器（6或10Mv—X线），常规分割剂量每日1次，每次2Gy，每周5次，总剂量64～68Gv，治疗组患者在放疗期问每周给予NDP30mg／m2静脉滴注化疗，对照组按照计划给予单纯放疗。结果：治疗组患者中位生存期为45．00个月（95％CI：42．19～47．81），生存率为76．67％，而对照组患者为38．50个月（95％CI：35．86～41．14），生存率为65．38％，生存曲线显示在放疗中给予奈达铂增敏组生存期优于单纯放疗组，经Log—rank检验，两者生存期比较差异有统计学意义（P〈0．05）。两组病例均未见3级或以上明显毒副作用；2级或以下毒副作用：治疗组22例，对照组19例，差异无显著性（P〉0．05）。结论：同时应用放疗和敏感性化疗药治疗食道癌，可提高对肿瘤局部的控制效果，提高生存率。

Reinforcement Effect of Nedaplatin for Radiotherapy of Esophageal Cancer

Objective： To investigate the curative effect and toxicity of nedapLatin combined with radiation therapy on patients with esophageal carcer. Methods：56 patients were randomly divided into two groups：RT plus nedaplatin （RT＋N）group and radiotherapy（RT） group. The RT＋N group was given nedaplatin 30mg / m2,once per week,in the course of RT. The RT（conventional RT）was carried out by linear accelerator（6MV-Xray）to irradiate the esophageal carcer to64 - 68Gy in both groups. Results：The complete response （CR）rates 2 months after therapy terminated were 60 % in RT＋N group and 23.1%in RT group （P〈0.05） ; The swallowing difficulties in RT＋N group realized improvement （P〈0. 05） ; Comparing with the RT group, Patients in RT＋N group had significantly longer mean survival （ P 〈0. 05, log rank test）. Toxicity in two groups were well tolerated in majority of patients. Conclusion： Nedaplatin is effective in increasing tumor radiation sensitivity and prolonging the survival of the patients with esophageal carcer and the toxicity is Well-tolerated.